Cargando…
Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver trans...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060654/ https://www.ncbi.nlm.nih.gov/pubmed/33897422 http://dx.doi.org/10.3389/fphar.2021.634087 |
_version_ | 1783681408113311744 |
---|---|
author | Minici, Roberto Ammendola, Michele Manti, Francesco Siciliano, Maria Anna Minici, Marco Komaei, Iman Currò, Giuseppe Laganà, Domenico |
author_facet | Minici, Roberto Ammendola, Michele Manti, Francesco Siciliano, Maria Anna Minici, Marco Komaei, Iman Currò, Giuseppe Laganà, Domenico |
author_sort | Minici, Roberto |
collection | PubMed |
description | According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The mean time-to-downstaging was 19.2 months, with six patients successfully downstaged. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. Twenty-two patients experienced adverse events after chemoembolization. The median OS and safety of DSM-TACE in this study are comparable with other published investigations in this field. Furthermore, 12% of patients were successfully downstaged. Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial. |
format | Online Article Text |
id | pubmed-8060654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80606542021-04-23 Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 Minici, Roberto Ammendola, Michele Manti, Francesco Siciliano, Maria Anna Minici, Marco Komaei, Iman Currò, Giuseppe Laganà, Domenico Front Pharmacol Pharmacology According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The mean time-to-downstaging was 19.2 months, with six patients successfully downstaged. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. Twenty-two patients experienced adverse events after chemoembolization. The median OS and safety of DSM-TACE in this study are comparable with other published investigations in this field. Furthermore, 12% of patients were successfully downstaged. Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8060654/ /pubmed/33897422 http://dx.doi.org/10.3389/fphar.2021.634087 Text en Copyright © 2021 Minici, Ammendola, Manti, Siciliano, Minici, Komaei, Currò and Laganà. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Minici, Roberto Ammendola, Michele Manti, Francesco Siciliano, Maria Anna Minici, Marco Komaei, Iman Currò, Giuseppe Laganà, Domenico Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title | Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title_full | Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title_fullStr | Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title_full_unstemmed | Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title_short | Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 |
title_sort | safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (dsm-tace) in the downstaging of intermediate-stage hepatocellular carcinoma (hcc) in patients with a child-pugh score of 8-9 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060654/ https://www.ncbi.nlm.nih.gov/pubmed/33897422 http://dx.doi.org/10.3389/fphar.2021.634087 |
work_keys_str_mv | AT miniciroberto safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT ammendolamichele safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT mantifrancesco safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT sicilianomariaanna safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT minicimarco safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT komaeiiman safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT currogiuseppe safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 AT laganadomenico safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89 |